


Claims

1. A compound of formula (I)



Formula (I)

5 wherein

R¹ represents hydrogen or methyl;

R² represents methyl, bromo, chloro, or cyano;

or a pharmaceutically acceptable salt thereof.

10 2. A compound according to claim 1; wherein R¹ represents hydrogen;
or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1; wherein R¹ represents methyl;
or a pharmaceutically acceptable salt thereof.

15

4. A compound according to any one of claims 1 to 3; wherein R² represents methyl;
or a pharmaceutically acceptable salt thereof.

5. A compound according to any one of claims 1 to 3; wherein R² represents chloro;

20 or a pharmaceutically acceptable salt thereof.

6. A compound according to any one of claims 1 to 3; wherein R² represents cyano;
or a pharmaceutically acceptable salt thereof.

7. A compound according to claim 1 selected from the group consisting of:

4-{6-[2-(2-Methyl-indol-1-yl)-ethylamino]-pyrimidin-4-yl}-benzoic acid;

4-{6-[2-(2-Cyano-indol-1-yl)-ethylamino]-pyrimidin-4-yl}-benzoic acid;

4-{6-[2-(2,7-Dimethyl-indol-1-yl)-ethylamino]-pyrimidin-4-yl}-benzoic acid;

5 4-{6-[2-(2-Chloro-indol-1-yl)-ethylamino]-pyrimidin-4-yl}-benzoic acid; and

4-{6-[2-(2-Bromo-indol-1-yl)-ethylamino]-pyrimidin-4-yl}-benzoic acid;

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising, as active principle, a compound according to any one of claims 1 to

10 7, or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

9. A compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for use as a medicament.

15 10. Use of a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of diseases selected from the group consisting of cancer; pain; endometriosis; autosomal dominant polycystic kidney disease; acute ischemic syndromes in atherosclerotic patients; pneumonia; and neurodegenerative diseases; or for the control of female fertility.

20 11. Use of a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of a cancer selected from melanoma; lung cancer; bladder cancer; renal carcinomas; gastro-intestinal cancers; endometrial cancer; ovarian cancer; cervical cancer; and neuroblastoma.

25

12. Use of a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for modulating an immune response in a subject having a tumor; wherein said medicament reactivates the immune system in the tumor of said subject.

30

13. Use of a compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention or treatment of cancer; wherein said compound is to be used in combination with a modulator of the PGE₂ receptor EP₄; and, in addition, optionally in combination with one or more chemotherapy agents and / or radiotherapy and / or targeted therapy.